BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8959080)

  • 21. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low synthesis rate of type I procollagen is normalized during active back rehabilitation.
    Hupli M; Hurri H; Luoto S; Risteli L; Vanharanta H; Risteli J
    Spine (Phila Pa 1976); 1997 Apr; 22(8):850-4. PubMed ID: 9127916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
    Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal calcium absorption and bone metabolism in young adult men with childhood-onset growth hormone deficiency.
    de Boer H; Blok GJ; Popp-Snijders C; Sips A; Lips P; van der Veen E
    J Bone Miner Res; 1998 Feb; 13(2):245-52. PubMed ID: 9495517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normal serum indices of bone collagen biosynthesis and degradation in small for gestational age infants.
    Namgung R; Tsang RC; Sierra RI; Ho ML
    J Pediatr Gastroenterol Nutr; 1996 Oct; 23(3):224-8. PubMed ID: 8890070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
    Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
    Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.
    Conti A; Sartorio A; Ferrero S; Ferrario S; Ambrosi B
    J Endocrinol Invest; 1996 Feb; 19(2):127-30. PubMed ID: 8778165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Net fluxes over working thigh of hormones, growth factors and biomarkers of bone metabolism during short lasting dynamic exercise.
    Brahm H; Piehl-Aulin K; Saltin B; Ljunghall S
    Calcif Tissue Int; 1997 Feb; 60(2):175-80. PubMed ID: 9056167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen.
    Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
    Clin Exp Rheumatol; 2000; 18(2):215-9. PubMed ID: 10812494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
    Wilton P
    Acta Paediatr Suppl; 1992 Sep; 383():137-42. PubMed ID: 1281024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotropin-releasing hormone analog and cyproterone acetate.
    Hertel NT; Stoltenberg M; Juul A; Main KM; Müller J; Nielsen CT; Lorenzen I; Skakkebaek NE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):924-7. PubMed ID: 8473407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone treatment in adults with GH deficiency: effects on new biochemical markers of bone and collagen turnover.
    Sartorio A; Conti A; Monzani M; Morabito F; Faglia G
    J Endocrinol Invest; 1993 Dec; 16(11):893-8. PubMed ID: 8144866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome.
    Piovesan A; Terzolo M; Reimondo G; Pia A; Codegone A; Osella G; Boccuzzi A; Paccotti P; Angeli A
    Horm Metab Res; 1994 May; 26(5):234-7. PubMed ID: 8076906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide.
    Heuck C; Wolthers OD; Hansen M; Kollerup G
    Steroids; 1997 Oct; 62(10):659-64. PubMed ID: 9381513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan.
    Abildgaard N; Nielsen JL; Heickendorff L
    Am J Hematol; 1994 Jul; 46(3):173-8. PubMed ID: 8192146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Procollagen I carboxyterminal propeptide (PICP) as a bone formation marker and carboxyterminal telopeptide of type I collagen (ICTP) as a bone degradation marker in children with chronic renal failure under conservative therapy.
    Polak-Jonkisz D; Zwolińska D; Bednorz R; Owczarek H; Szymańska A; Nahaczewska W
    Med Sci Monit; 2003 Jan; 9(1):CR19-23. PubMed ID: 12552245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levels of carboxy terminal propeptide of type I procollagen and pyridinoline cross-linked telopeptide of type I collagen in healthy school children.
    Kikuchi T; Hashimoto N; Kawasaki T; Kataoka S; Takahashi H; Uchiyama M
    Acta Paediatr; 1998 Aug; 87(8):825-9. PubMed ID: 9736228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults.
    Kann P; Piepkorn B; Schehler B; Andreas J; Lotz J; Prellwitz W; Beyer J
    Clin Endocrinol (Oxf); 1998 May; 48(5):561-8. PubMed ID: 9666867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.